Juan M. Zapata

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Indole-3-carbinol is an inhibitor of KV1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells.

Indole-3-carbinol is an inhibitor of KV1.3 potassium voltage-gated channel activity in chronic lymphocytic leukemia cells.

Journal: European journal of pharmacology

Published: July 30, 2025

Editorial: Community series in mouse models of B cell malignancies, volume II.

Editorial: Community series in mouse models of B cell malignancies, volume II.

Journal: Frontiers in immunology

Published: August 30, 2024

Reprogramming of the LXRα Transcriptome Sustains Macrophage Secondary Inflammatory Responses.

Reprogramming of the LXRα Transcriptome Sustains Macrophage Secondary Inflammatory Responses.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: September 28, 2023

CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.

CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects.

Journal: Science advances

Published: August 18, 2023

Editorial: Mouse Models of B Cell Malignancies.

Editorial: Mouse Models of B Cell Malignancies.

Journal: Frontiers in immunology

Published: October 05, 2021

JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.

JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 03, 2021

The Traf2DNxBCL2-tg Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart.

The Traf2DNxBCL2-tg Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart.

Journal: Frontiers in immunology

Published: November 09, 2020

Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.

Case Report: An EGFR-Targeted 4-1BB-agonistic Trimerbody Does Not Induce Hepatotoxicity in Transgenic Mice With Liver Expression of Human EGFR.

Journal: Frontiers in immunology

Published: October 05, 2020

CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.

CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110.

Journal: Journal of hematology & oncology

Published: November 08, 2019

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.

Journal: Frontiers in immunology

Published: September 03, 2018

Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.

Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.

Journal: Frontiers in immunology

Published: September 01, 2018

Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.

Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.

Journal: Cancer gene therapy

Published: August 03, 2018

Showing 1-12 of 23

Last Updated: 09/26/2026